Annotation Detail
Information
- Associated Genes
- FLT3
- Associated Variants
-
FLT3 p.Asp835Tyr (p.D835Y)
(
ENST00000241453.12 )
FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) - Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- 13 patients with relapsed or chemo-refractory FLT3-ITD+ AML were treated with sorafenib (200-400 mg twice daily). 12 patients responded, but sorafenib response was lost in most patients after 72 (range 54-287) days. Leukemia initiating cells bearing the D835 mutation expanded during sorafenib treatment and dominated during the subsequent clinical resistance. Results were recapitulated in-vivo.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1039
- Gene URL
- https://civic.genome.wustl.edu/links/genes/24
- Variant URL
- https://civic.genome.wustl.edu/links/variants/437
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Sorafenib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 22368270
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Sorafenib | Resitance or Non-Reponse | true |